Dexamethasone-palmitate-DXP-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEDexamethasonepalmitateCat.No.:HY-128922CASNo.:14899-36-6Synonyms:DXP分?式:C??H??FO?分?量:630.87作?靶點(diǎn):Others作?通路:Others儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:50mg/mL(79.26mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.5851mL7.9256mL15.8511mL5mM0.3170mL1.5851mL3.1702mL10mM0.1585mL0.7926mL1.5851mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.08mg/mL(3.30mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:2.08mg/mL(3.30mM);Suspendedsolution;Needultrasonic3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(3.30mM);ClearsolutionBIOLOGICALACTIVITY?物活性Dexamethasonepalmitate(DXP)Dexamethasone(HY-14648)的前體藥物。Dexamethasonepalmitate可?于炎癥的研究。體外研究Dexamethasonepalmitate(100μg/mL;48h)affectscytokinesconcentrationofRAW264.7cells[1].CellViabilityAssay[1]CellLine:RAW264.7cellsConcentration:100μg/mLIncubationTime:48hoursResult:Showedvitroanti-inflammatoryeffectsanddecreasedLPS-inducedMCP-1andTNF-αconcentrationinRAW264.7cells.體內(nèi)研究Dexamethasonepalmitate(1280μg;IVTinjectiononce)showsdifferentdistributioninoculartissueatdifferenttimes[2].Dexamethasonepalmitate(280-1280μg;IVTinjectiononce)affectsVEGF-inducedvascularhyperpermeability[2].AnimalModel:NewZealandWhiterabbits[2]Dosage:1280μgAdministration:IVTinjection;1280μgonceResult:Mostlydistributedinvitreousandstillexistedtill9months.Theleastdistributedinaqueoushumorandalmostdisappearedtill6months.AnimalModel:NewZealandWhiterabbitswithVEGFinjection[2]Dosage:280,560and1280μgAdministration:IVTinjection;280-1280μgonceResult:After9monthsadministrationVEGF-inducedvascularpermeabilitywascontrolledataconcentrationof1280μg,besides280and560μgalsoreducedVEGF-inducedvascular2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEhyperpermeabilityafteradministrationfor4months.REFERENCES[1].LorscheiderM,etal.Dexamethasonepalmitatenanoparticles:Anefficienttreatmentforrheumatoidarthritis.JControlRelease.2019Feb28;296:179-189.[2].DaullP,etal.Apreliminaryevaluationofdexamethasonepalmitateemulsion:anovelintravitrealsustaineddeliveryofcorticosteroidfortreatmentofmacularedema.JOculPharmacolTher.2013Mar;29(2):258-69.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformed